Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting - Lexicon Pharmaceuticals (NASDAQ:LXRX)
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of Managed Care &